1. Home
  2. DYAI vs GBIO Comparison

DYAI vs GBIO Comparison

Compare DYAI & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DYAI
  • GBIO
  • Stock Information
  • Founded
  • DYAI 1979
  • GBIO 2016
  • Country
  • DYAI United States
  • GBIO United States
  • Employees
  • DYAI N/A
  • GBIO N/A
  • Industry
  • DYAI Biotechnology: Biological Products (No Diagnostic Substances)
  • GBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • DYAI Health Care
  • GBIO Health Care
  • Exchange
  • DYAI Nasdaq
  • GBIO Nasdaq
  • Market Cap
  • DYAI 28.3M
  • GBIO 29.5M
  • IPO Year
  • DYAI 2004
  • GBIO 2020
  • Fundamental
  • Price
  • DYAI $1.13
  • GBIO $4.51
  • Analyst Decision
  • DYAI Strong Buy
  • GBIO Strong Buy
  • Analyst Count
  • DYAI 1
  • GBIO 4
  • Target Price
  • DYAI $6.00
  • GBIO $73.33
  • AVG Volume (30 Days)
  • DYAI 203.9K
  • GBIO 206.6K
  • Earning Date
  • DYAI 08-12-2025
  • GBIO 08-06-2025
  • Dividend Yield
  • DYAI N/A
  • GBIO N/A
  • EPS Growth
  • DYAI N/A
  • GBIO N/A
  • EPS
  • DYAI N/A
  • GBIO N/A
  • Revenue
  • DYAI $3,554,344.00
  • GBIO $24,556,000.00
  • Revenue This Year
  • DYAI $22.56
  • GBIO N/A
  • Revenue Next Year
  • DYAI $30.95
  • GBIO N/A
  • P/E Ratio
  • DYAI N/A
  • GBIO N/A
  • Revenue Growth
  • DYAI 57.59
  • GBIO 146.47
  • 52 Week Low
  • DYAI $0.91
  • GBIO $3.00
  • 52 Week High
  • DYAI $2.20
  • GBIO $34.35
  • Technical
  • Relative Strength Index (RSI)
  • DYAI 62.78
  • GBIO 54.72
  • Support Level
  • DYAI $1.08
  • GBIO $4.05
  • Resistance Level
  • DYAI $1.20
  • GBIO $5.10
  • Average True Range (ATR)
  • DYAI 0.08
  • GBIO 0.63
  • MACD
  • DYAI 0.02
  • GBIO 0.02
  • Stochastic Oscillator
  • DYAI 50.00
  • GBIO 35.65

About DYAI Dyadic International Inc.

Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: